| Prev Close | 171.39 |
| Open | 170.94 |
| Day Low/High | 168.91 / 171.00 |
| 52 Wk Low/High | 130.09 / 181.81 |
| Volume | 243.24K |
| Avg Volume | 3.24M |
| Exchange | NASDAQ |
| Shares Outstanding | 729.67M |
| Market Cap | 124.07B |
| EPS | 10.30 |
| P/E Ratio | 15.49 |
| Div & Yield | 4.60 (2.70%) |
Latest News
Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration
Filing for ABP 980, a Biosimilar Candidate to Herceptin® (trastuzumab), Supported by Phase 3 Data in Patients With HER2-Positive Early Breast Cancer
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
FDA Priority Review Status Underscores Need to Reduce Heart Attacks and Strokes
Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens
U.S. stock futures turn higher on Tuesday following earnings from Alphabet.
U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead
Wall Street's first glimpse at the second quarter.
Intermediate Trade: QQQ
Try this bearishly biased, out-of-the-money put spread on the Nasdaq 100 ETF.
FDA Accepts Biologics License Application For Aimovig™ (erenumab)
Aimovig is an Investigative Migraine-Specific Preventive Therapy Designed for Patients With High Unmet Need
Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation
Array to Advance Preclinical Program for Autoimmune Disorders
Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label
Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent and Increased Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)
First Amgen and Allergan Oncology Biosimilar Candidate to be Reviewed by U.S. FDA Advisory Committee
Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone
FDA Grants Full Approval For BLINCYTO® (blinatumomab) To Treat Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
BLINCYTO is the First-and-Only Bispecific T Cell Engager (BiTE®) Immunotherapy to Demonstrate Superior Overall Survival Versus Standard of Care Chemotherapy
Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket
Two Diagnostic Companies Will Receive Lab Space and Other Benefits at San Francisco Life Sciences Incubator
First Witness to Testify in Pharma Bro's Trial Felt 'Betrayed'
Sarah Hassan, daughter of pharmaceutical executive Fred Hassan, was ignored by Shkreli for nearly a year before she received returns on her original investment.
Another Steep Selloff in Tech Stocks Wipes Out Nasdaq's June Gains
A tech selloff yields big Wall Street losses.
FDA Approves Vectibix® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer
Vectibix Demonstrated an Improvement in Overall Survival in Patients With Wild-Type RAS Metastatic Colorectal Cancer
Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan
Tech, healthcare slide weighs on rest of markets.
Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly
Healthcare's slide weighs on rest of markets.
How President Trump Has Sent Biotech Stocks Soaring
The iShares NASDAQ Biotechnology Index ended the five days ended Friday, June 23 up 26% to close at $370.74.
Biotech Movers: Regeneron Slides Back After Big Gains
The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.
